Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL323394 | 1.00 | — | — | |
| SCHEMBL19689400 | 1.00 | HDAC4 (0.34) | HDAC4HDAC2HDAC8HDAC6TRPA1 | |
| SCHEMBL17653495 | 1.00 | HDAC4 (0.34) | HDAC4HDAC2HDAC8HDAC6TRPA1 | |
| SCHEMBL31016738 | 1.00 | HDAC4 (0.34) | HDAC4HDAC2HDAC8HDAC6TRPA1 | |
| SCHEMBL4578692 | 1.00 | HDAC4 (0.34) | HDAC4HDAC2HDAC8HDAC6TRPA1 | |
| SCHEMBL11952530 | 1.00 | HDAC4 (0.34) | HDAC4HDAC2HDAC8HDAC6TRPA1 | |
| SCHEMBL17653494 | 1.00 | HDAC4 (0.34) | HDAC4HDAC2HDAC8HDAC6TRPA1 | |
| SCHEMBL2194008 | 1.00 | HDAC4 (0.34) | HDAC4HDAC2HDAC8HDAC6TRPA1 | |
| SCHEMBL4578689 | 1.00 | HDAC4 (0.34) | HDAC4HDAC2HDAC8HDAC6TRPA1 | |
| SCHEMBL20542554 | 1.00 | HDAC4 (0.34) | HDAC4HDAC2HDAC8HDAC6TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116829195-A | Tracer compound and preparation method thereof | 图尔库大学 | 2023-09-29 | — | — | CN | disclosed |
| US-20190241822-A1 | COMPOSITION FOR REMOVING IRON SULFIDE | KURARAY CO., LTD. (JP) | 2019-08-08 | — | — | US | disclosed |
| EP-3486353-A1 | COMPOSITION FOR REMOVING IRON SULFIDE | Kuraray Co., Ltd. (JP) | 2019-05-22 | — | — | EP | disclosed |
| EP-2147007-A1 | STABLE CATALYST PRECURSOR OF RH COMPLEX CATALYSTS | Evonik Oxeno GmbH (DE) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008141853-A1 | STABLE CATALYST PRECURSOR OF RH COMPLEX CATALYSTS | EVONIK OXENO GMBH (DE) | 2008-11-27 | — | — | WO | disclosed |
| US-20050113414-A1 | 1-[1-((E)-1-Cyclooct-1-enyl)methylpiperidin-4-yl]-3-(3,4-dichlorophenyl)-urea; potent and selective modulators of CXCR3, a chemokine receptor; antagonists; treatment of conditions involving inappropriate T-cell trafficking; antiinflammatory, -arthritic agents, autoimmune diseases; antiallergens | CELLTECH R&D LIMITED (GB) | 2005-05-26 | — | — | US | disclosed |
| WO-2005003127-A1 | BICYCLIC HETEROAROMATIC DERIVATIVES AS MODULATORS OF CXCR3 FUNCTION | CELLTECH R & D LIMITED (GB) | 2005-01-13 | — | — | WO | disclosed |
| EP-1478359-A1 | PIPERIDIN-4-YL UREA DERIVATIVES AND RELATED COMPOUNDS AS CHEMOKINE RECEPTOR INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Celltech R & D Limited (GB) | 2004-11-24 | — | — | EP | disclosed |
| EP-0990653-B1 | 2-OXOIMIDAZOLE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2004-09-15 | — | — | EP | disclosed |
| US-6627651-B1 | Exhibiting preventive and therapeutic effects against HIV infectious diseases wherein R1 is an optionally substituted five- or six-membered ring group; X1 is a free valency or the like; W is a divalent group and inhibitors of HIV (human | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-09-30 | — | — | US | disclosed |
| US-20030171413-A1 | Bicyclic heteroaromatic derivatives for the treatment of immune and inflammatory disorders | CELLTECH R & D LIMITED (GB) | 2003-09-11 | — | — | US | disclosed |
| WO-2003070242-A1 | PIPERIDIN-4-YL UREA DERIVATIVES AND RELATED COMPOUNDS AS CHEMOKINE RECEPTOR INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | CELLTECH R & D LIMITED (GB) | 2003-08-28 | — | — | WO | disclosed |
| EP-1311502-A1 | BICYCLIC HETEROAROMATIC DERIVATIVES FOR THE TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | Celltech R&D Limited (GB) | 2003-05-21 | — | — | EP | disclosed |
| WO-2002016353-A1 | BICYCLIC HETEROAROMATIC DERIVATIVES FOR THE TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | CELLTECH R & D LIMITED (GB) | 2002-02-28 | — | — | WO | disclosed |
| EP-1182195-A1 | CYCLIC COMPOUNDS AND USES THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2002-02-27 | — | — | EP | disclosed |
| US-6258825-B1 | ANALGESIC, A RELIEVER AGAINST TOLERANCE TO A NARCOTIC ANALGESIC REPRESENTED BY MORPHINE, REMEDY FOR PARKINSONISM, A REMEDY FOR CHOREA, AN ANTIDEPRESSANT, A REMEDY FOR DIABETES INSIPIDUS, A REMEDY FOR POLYURIA, OR HYPOTENSION | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2001-07-10 | — | — | US | disclosed |
| US-6140338-A | FOR TREATING ACUTE INFLAMMATORY DISEASES, CHRONIC INFLAMMATORY DISEASES, ACQUIRED IMMUNE DEFICIENCY SYNDROME, CANCER, ISCHEMIC REFLOW DISORDER AND/OR ARTERIOSCLEROSIS | BANYU PHARMACEUTICAL, CO., LTD. (JP) | 2000-10-31 | — | — | US | disclosed |
| EP-0990653-A1 | 2-OXOIMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2000-04-05 | — | — | EP | disclosed |
| EP-0916668-A1 | CHEMOKINE RECEPTOR ANTAGONISTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113414-A1 | 1-[1-((E)-1-Cyclooct-1-enyl)methylpiperidin-4-yl]-3-(3,4-dichlorophenyl)-urea; potent and selective modulators of CXCR3, a chemokine receptor; antagonists; treatment of conditions involving inappropriate T-cell trafficking; antiinflammatory, -arthritic agents, autoimmune diseases; antiallergens | CXCR3, ACKR3, CCR1 | HDAC4 4481/4885HDAC2 4662/4885HDAC8 4451/4885 |
| US-20030171413-A1 | Bicyclic heteroaromatic derivatives for the treatment of immune and inflammatory disorders | CCR1, CCR3, CCRL2 | HDAC4 3546/4885HDAC2 1431/4885HDAC8 3693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.